Orion Corp
KRX:271560
Operating Margin
Orion Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
|
Orion Corp
KRX:271560
|
4.7T KRW |
18%
|
|
| JP |
G
|
Goyo Foods Industry Co Ltd
TSE:2230
|
53.2T JPY |
8%
|
|
| CH |
|
Nestle SA
SIX:NESN
|
232.4B CHF |
17%
|
|
| US |
|
Mondelez International Inc
NASDAQ:MDLZ
|
89B USD |
18%
|
|
| FR |
|
Danone SA
PAR:BN
|
45.6B EUR |
13%
|
|
| ZA |
T
|
Tiger Brands Ltd
JSE:TBS
|
42.7B Zac |
8%
|
|
| US |
|
Kraft Heinz Co
NASDAQ:KHC
|
35.9B USD |
21%
|
|
| US |
|
Hershey Co
NYSE:HSY
|
34.5B USD |
26%
|
|
| US |
|
General Mills Inc
NYSE:GIS
|
32.7B USD |
18%
|
|
| CN |
|
Foshan Haitian Flavouring and Food Co Ltd
SSE:603288
|
227.9B CNY |
25%
|
|
| CH |
|
Chocoladefabriken Lindt & Spruengli AG
SIX:LISN
|
26.6B CHF |
17%
|
Orion Corp
Glance View
Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Orion Corp's most recent financial statements, the company has Operating Margin of 17.5%.
You don't have any saved screeners yet